OR WAIT null SECS
ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.
-ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.
Collectively, the trials are referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. One trial (TG-MV-006) is taking place in the United States and the other (TG-MV-007) is taking place in Europe and the United States. Both of the MIVI-TRUST trials are multicenter, randomized, placebo-controlled, double-masked trials evaluating 125 µg of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The endpoint will be measured using optical coherence tomography.
The company expects to present results from the TG-MV-006 study in the second quarter of this year and results from the TG-MV-007 in the third quarter.